Title: COVID-19 and cirrhosis: a fatal case of viral peritonitis and disseminated infection

Running head: Cirrhosis & COVID-19: evidence of viral peritonitis

Authors: Victor C. Passarelli[1], Ana H. Perosa[1], Luciano Luna[1], Danielle D. Conte[1], Oliver A. Nascimento[2], Jaquelina Ota-Arakaki[2], Nancy Bellei[1].

Affiliations:

[1] Infectious Diseases Division. Department of Medicine. Federal University of São Paulo, São Paulo, Brazil

[2] Pulmonology Division. Department of Medicine. Federal University of São Paulo, Brazil.

Corresponding author:

Victor C Passarelli,

Address for correspondence: Virology Laboratory, Division of Infectious Diseases, Department of Medicine, Federal University of São Paulo, Rua Pedro de Toledo, 781, 15h floor. E-mail: vicpassarelli@hotmail.com.

Abstract:

Pathogenesis and clinical presentation of Coronavirus Disease-19 outside the respiratory tract remain to be understood, especially in the immunocompromised.

We report an unique case of cirrhosis decompensation with ascites and unprecedented evidence of SARS Coronavirus-2 peritonitis and disseminated infection, demonstrated by viral RNA detection in peritoneal fluid, as well as in blood serum, nasopharyngeal and stool specimens.

Word count: 55

Keywords: coronavirus, ascites, cirrhotic, viral peritonitis.

Full text

Introduction

SARS Coronavirus-2 affects primarily upper and lower respiratory tract, but detection in different clinical specimens has raised important insights about its kinetics and pathogenesis[1]. However, virus' replication in other body sites and pathogenetic details still remain to be understood[2], although endothelial injury with intracellular virus as well as immune system dysregulation have been described[3,4].

In that respect, immunocompromising conditions, such as cirrhosis. can present with even more severe consequences[5] when combined with dysfunctions observed in COVID-19.

We report an unique case of cirrhosis decompensation with ascites and evidence of viral peritonitis and disseminated infection in a kidney transplant patient, demonstrated by viral RNA detection in peritoneal fluid, as well as in blood serum, nasopharyngeal and stool specimens.

Case report

A 75-year-old white male with a history of hypertension and a kidney transplantation in 2017 presented in the emergency department on May 18th, 2020, five days following the onset of dry cough and progressive dyspnea, without fever or other respiratory or gastrointestinal tract symptoms. He was on immunossupressive therapy with 4 mg tacrolimus and 5 mg prednisone. Physical examination at admission revealed an axillary temperature of 37.1ºC, blood pressure of 160/90 mmHg, heart rate of 104 per minute, respiratory rate of 25 breaths per minute and oxygen saturation of 92% while breathing ambient air. Abdominal examination demonstrated mild ascites with collateral circulation.

He was diagnosed in 2018 with liver cirrhosis, portal hypertension and thrombosis, without a conclusive aetiology, but denied any prior decompensation. His previous serologies were negative for HIV, Hepatitis C, Syphilis, Schistosomiasis and he had an spontaneous cure of Hepatitis B with undetectable viral load.

Initial laboratory findings showed normal white cell count but severe lymphopenia (162 per mm^3) as well as other cirrhosis dysfunctions such as thrombocytopenia, increased international normalized ratio (INR) and hypoalbuminemia. Creatinine was 1.5 times its baseline value (2.4 mg/dl), procalcitonin was elevated at 3.92 ng/dl and d-dimer was above 20 µg/mL (maximum test detection). Additional laboratory exams may be seen on Table 1.

Chest computed tomography scan showed bilateral ground glass opacities with some areas of consolidation and specimens from his nasopharyngeal swab were positive for COVID-19 on Real Time Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR).

Supplementary oxygen (O2) with a nasal cannula was administered at 2 L/min and his pulse oximetry went up to 97% and he was started on ceftriaxone and clarithromycin. Tacrolimus was suspended and prednisone dose was increased to 30 mg daily.

On day 2 of hospitalization (day 8 of illness) his breathing pattern worsened, as he needed an increase in nasal oxygen flow to 6 L/min, and so did his ascites, which then made his abdomen tense and painful. A diagnostic and therapeutic abdominal paracentesis was performed and 2 litres of citrine yellow ascitic fluid were subsequently removed. Laboratory analysis showed a total cell count of 133 per mm^3 (macrophages: 60%, mesotelyocytes: 24% and lymphocytes: 16%) and a serum-ascites albumin gradient value of 2. RT-PCR for COVID-19 in peritoneal fluid was positive, as well as in his serum and fecal samples (table 2). A rapid serological test performed on day 10 of symptoms was positive for IgM and IgG antibodies.

On day 4, he required intubation as his respiratory status worsened further (PaO2/FiO2 ratio: 110). His ventilation parameters improved in the following days but his renal dysfunction did not and he was started on hemodialysis. The patient died on day 16 due to a refractory septic shock.

Methods

Nasal and oropharyngeal swabs were collected and stored in 2 mL of sterile Ringer's lactate solution prior to RNA extraction with QIAamp Viral RNA Mini Kit (QIAGEN, Hilden, Germany), following manufacturer's instructions. Virus screening was carried out with AgPath-ID One-Step RT-PCR Reagents on 20 µL of total reaction volume. SARS-CoV-2 detection was performed with oligonucleotides described by the Centers for Disease Control and Prevention (CDC). Serum was collected in a serum separator tube and then centrifuged according to CDC guidelines. Feces and ascitic fluid were collected with sterile specimen containers and all three specimens tested for SARS-CoV-2 at the same protocol. Rapid serological test was performed with serum sample following manufacturer’s instructions (Zhuhai Livzon Diagnostics).

This case report was approved by Local Ethics Committee.

Results

Specimens from nasopharyngeal swab obtained on day 5 of patient’s illness were positive for SARS-Cov-2 (table 2). Low cycle threshold (Ct) values (14-15) suggest high levels of virus. Peritoneal fluid from day 7 was also positive (Ct, 34-38), serum samples collected on day 9 and

10 were positive for both SARS-CoV-2 (Ct, 31-32) and IgM/IgG antibodies, respectively. Stool collected on day 10 was positive as well (Ct, 25-26).

Discussion

A great variety of clinical features have been attributed to coronavirus disease including cough and dyspnea[2], which were similar to the ones reported by this patient. Pneumonia is the most common feature on severe disease[2] and, sometimes, it can lead to multi-organ disease syndrome, including heart, kidney and liver dysfunctions[4]. One possible explanation for that is endothelial injury associated with intracelular viruses, previously described in lung autopsy reports[3], which also appears to incite a high rate of thrombotic events[6].We assume this could partially explain further aggravation of a previous portal vein thrombosis observed with this patient, which would justify the worsening of his ascites. Moreover, we also hypothesize direct viral damage had a potential role on his initial clinical presentation, which could be considered a viral peritonitis, as SARS CoV-2 RNA was detected in his ascitic fluid. Interestingly, reports on cirrhotic patients with COVID-19 show a high rate of decompensation with ascites[5], but this is the first report of such finding.

Furthermore, viral detection in blood samples from immunocompetent patients suggests systemic infection is sometimes possible[1] and, since solid-organ transplant patients on immunosuppressive therapy have impaired T cell immunity, higher rates of replication would be expected[8]. Therefore we hypothesize a combination of a potentially systemic infection and immunosuppression in addition to cirrhosis' immune dysfunction[5] could have contributed to a disseminated infection in this patient. In spite of that, he presented with seemingly adequate

humoral immune response as he was able to produce IgM and IgG antibodies by day 10 of symptoms onset, which is consonant with previous literature[9,10].

Unfortunately, other dysfunctions observed with COVID-19[2] prolonged hospitalization and led to complications which were fatal to this patient..

Conclusion

This unprecedented case report adds new information on COVID-19 pathogenesis and highlights the need for more research about viral dynamics as well as clinical outcomes, especially in patients with end-stage liver disease.

Acknowledgments

This research received support from the Coordination for the Improvement of Higher Education Personnel (CAPES) and the National Council for Scientific and Technological Development (CNPq).

Authors declare no conflict of interest.

References

1. Wang W, Xu Y, Gao R. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. JAMA. 2020;323(18):1843–1844. doi:10.1001/jama.2020.3786

2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506. https://doi.org/10.1016/S0140-6736(20)30183-5
3. Ackermann M, Verleden S, Kuehnel M, Haverich A, Welte T, Laenger F, et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N Engl J Med.. 2020. https://doi.org/10.1056/NEJMoa2015432
4. Moon, C. Fighting COVID-19 exhausts T cells. Nat Rev Immunol. 2020;20:277 (2020). https://doi.org/10.1038/s41577-020-0304-7
5. Qi X, Liu Y, Wang J, Fallowfield JA, Wang J, Li X, et al Clinical course and risk factors for mortality of COVID-19 patients with pre-existing cirrhosis: a multicentre cohort study. Gut BMJ. . 2020. https://doi.org/10.1016/s0140-6736(20)30566-3
6. Middeldorp S, Coppens M, van Haaps TF, Foppen M, Vlaar AP, Müller MCA, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J ThrombHaemost. 2020;Online ahead of print. https://doi.org 10.1111/jth.14888./
7. Wölfel R, Corman VM, Guggemos W, Selmeier M, Zange S, Müller M, et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020;581:465–469. https://doi.org/10.1038/s41586-020-2196-x
8. Uematsu J, Sakai SK, Kihira NS, Yamamoto H, Hirai K, Kawano M, et al. Inhibitions of human parainfluenza virus type 2 replication by ribavirin and mycophenolate mofetil are restored by guanosine and S□(4□nitrobenzyl)□6□thioinosine. Drug Discov Ther.2019;13:314-321. https://doi.org/10.5582/ddt.2019.01084

9. Ma H, Zeng W, He H, Zhao D, Jiang D, Zhou P, et al. Serum IgA, IgM, and IgG responses in COVID-19. Cell Mol Immunol. 2020. https://doi.org/ https://doi.org/10.1038/s41423-020-0474-z

10. Fung, M, Chiu, CY, DeVoe, C, Doernberg, SB, Schwartz, BS, Langelier, C, et al. (2020), Clinical Outcomes and Serologic Response in Solid Organ Transplant Recipients with COVID□19: A Case Series from the United States. Am J Transplant. 2020. https://doi.org/10.1111/ajt.16079/

Table 1. Evolutive blood test results on initial days of hospitalization compared with previous results.

Laboratory findings		22/04/2020	18/05/2020	19/05/2020	20/05/2020	22/05/2020	23/05/2020
	Normal range	No symptoms	Day 1 of hospital	Day 2 of hospital	Day 3 of hospital	Day 5 of hospital	Day 6 of hospital
			Day 5 of illness	Day 6 of illness	Day 7 of illness	Day 9 of illness	Day 10 of illness
Absolute White-cell count (per mm³)	3500 - 10500	2560	5700	4580	7880	5430	6730
Absolute Neutrophil count (per mm³)	1700-8000	1802	5547	4278	7636	5197	6192
Absolute Lymphocyte count (per mm³)	900-2900	586	162	229	150	114	269
Platelet count (per mm³)	150000-450000	45000	48000	44000	56000	64000	63000
Hemoglobin (g/dL)	13,5 – 17,5	11,7	11,3	10,3	10,9	9,9	9,9
Hematocrit (%)	39 - 50	34	32	30	32,1	29	30,2
Other findings							
Procalcitonin (ng/mL)	< 0,06	-	-	3,92	-	-	-
Lactate Dehydrogenase (U/Liter)	< 250	-	366	-	-	-	-
D-dimer (ug/FEU)	< 0,5	-	>20	>20	-	>20	-
Troponin (pg/mL)	< 14	-	65	60	108		
Creatine kinase (U/Liter)	39 - 308	-	-	-	135	-	-
Creatinine (mg/dL)	0,7 – 1,2	2,5	3,68	4,15	4,55	4,89	4,68
Urea (mg/dL)	10 - 50	80	126	142	184	218	234

Total bilirubin (mg/dL)	0,3 - 1,2	1,19	-	0,67	-	0,49	0,47
Aspartate aminotransferase (U/Liter)	< 40	34	39	33	-	35	17
Alanine aminotransferase (U/Liter)	< 41	36	22	20	-	21	18
Gamma Glutamyl transferase (U/Liter)	<60	75	-	114	-	-	-
Albumin (g/dL)	3,5 – 5,2	-	-	2,6	-	-	-
International normalized ratio (INR)	0,8-1,2	1,35	1,25	1,34	-	-	1,34
Alpha Fetoprotein (ng/dL)	< 7	3,8		1,95	-	-	-
Sodium (mmol/L)	137 - 148	145	142	148	143	147	147
Potassium (mmol/L)	3,5 - 5	4,7	4,6	5,2	4,4	4,4	3,2
Calcium (mmol/L)	1,15 – 1,32	-	-	-	-	1,13	-

Table 2. Specimen tested for COVID-19 using RT-PCR technique according to date of exam.

Specimen	18/05/2020 Illness day 5	20/05/2020 Illness day 7	22/05/2020 Illness day 9	23/05/2020 Ilness day 10
Nasopharyngeal swab	Positive (CT 14-15)	-	-	
Peritoneal fluid	-	Positive (CT 34-38)	-	
Serum	-	-	Positive (CT 31--33)	
Stool	-	-	-	Positive (CT 25-26)

Sample was considered positive if cycle thresold (CT) value < 40. Lower values suggest higher viral loads.